

S4 Table. Clinicopathologic characteristics of patients with non–high-grade serous carcinoma

Characteristic	Total (n=134)	<i>BRCA</i> wild-type (n=116)	<i>BRCA</i> mutation (n=18)	p-value
Age (yr)	49.8±12.0	49.2±12.4	53.5±9.1	0.160
Parity	1.3±1.1	1.3±1.2	1.6±0.9	0.234
Origin				
Ovary	132 (98.5)	114 (98.3)	18 (100)	>0.999
Fallopian tube	2 (1.5)	2 (1.7)	0	
Peritoneum	0	0	0	
Hx of BC	12 (9.0)	8 (6.9)	4 (22.2)	0.057
Hx of other cancers	15 (11.2)	10 (8.6)	5 (27.8)	0.032
Family Hx of POFTC	5 (3.7)	1 (0.9)	4 (22.2)	0.001
Family Hx of BC	9 (6.7)	4 (3.4)	5 (27.8)	0.002
Family Hx of other cancers	33 (24.6)	26 (22.4)	7 (38.9)	0.147
FIGO stage				0.020
I	55 (41.0)	53 (45.7)	2 (11.1)	
II	20 (14.9)	15 (12.9)	5 (27.8)	
III	40 (29.9)	31 (26.7)	9 (50.0)	
IV	19 (14.2)	17 (14.7)	2 (11.1)	
Histology				0.223
Low-grade serous	11 (8.2)	10 (8.6)	1 (5.6)	
Endometrioid	43 (32.1)	37 (31.9)	6 (33.3)	
Mucinous	16 (11.9)	13 (11.2)	3 (16.7)	
Clear cell	42 (31.3)	40 (34.5)	2 (11.1)	
Mixed	14 (10.4)	10 (8.6)	4 (22.2)	
Others	8 (6.0)	6 (5.2)	2 (11.1)	
Tumor grade				0.756
1	30 (22.4)	27 (23.3)	3 (16.7)	
2	21 (15.7)	18 (15.5)	3 (16.7)	
3	77 (57.5)	65 (56.0)	12 (66.7)	
Unknown	6 (4.5)	6 (5.2)	0	
CA-125 (IU/mL)	179.0 (11.0-13,800)	171.0 (11.0-13,800)	356.0 (20.6-9,045.0)	0.146
Primary treatment strategy				0.664
PDS	122 (91.0)	106 (91.4)	16 (88.9)	
NAC	12 (9.0)	10 (8.6)	2 (11.1)	
Residual tumor after PDS/IDS				0.903
No gross	118 (88.1)	102 (87.9)	16 (88.9)	
<1 cm	12 (9.0)	10 (8.6)	2 (11.1)	
1-2 cm	1 (0.7)	1 (0.9)	0	
≥2 cm	2 (1.5)	2 (1.7)	0	
Unknown	1 (0.7)	1 (0.9)	0	
Recurrence ^{a)}	71 (53.0)	62 (53.4)	9 (50.0)	0.785
PSR ^{b)}	39 (29.1)	31 (26.7)	8 (44.4)	0.078
PRR	25 (18.7)	24 (20.7)	1 (5.6)	
Genetic test methods				0.524
Germline only	116 (86.6)	99 (85.3)	17 (94.4)	
Somatic only	13 (9.7)	12 (10.3)	1 (5.6)	
Both	5 (3.7)	5 (4.3)	0	
<i>BRCA1</i> mutational status				< 0.001
Wild-type	122 (91.0)	116 (100.0)	6 (33.3)	
Mutation	12 (9.0)	0	12 (66.7)	

<i>BRCA2</i> mutational status				< 0.001
Wild-type	128 (95.5)	116 (100)	12 (66.7)	
Mutation	6 (4.5)	0	6 (33.3)	

Values are presented as mean±SD, number (%), or median (range). Hx, history; BC, breast cancer; POFTC, peritoneal, ovarian, and fallopian tubal cancers; FIGO, International Federation of Gynecology and Obstetrics; CA-125, cancer antigen 125; PDS, primary debulking surgery; NAC, neoadjuvant chemotherapy; IDS, interval debulking surgery; PSR, platinum-sensitive recurrence; PRR, platinum-resistant recurrence; SD, standard deviation. ^{a)}Among the recurred, seven patients did not receive taxane- and platinum-based chemotherapy before, ^{b)}PSR was defined as relapse ≥ 6 months after completion of taxane- and platinum-based chemotherapy, whereas PRR as relapse < 6 months.